Emerging studies suggest this peptide, a dual agonist targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , appears to represent a significant step forward for obesity treatment. Early human tests have indicated considerable reductions in body mass , conceivably exceeding current weight-loss medications . Nevertheless